ロード中...
Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results
IMPORTANCE: Brentuximab vedotin is a monomethyl auristatin E–conjugated monoclonal antibody directed against CD30. It represents a potential treatment for the CD30(+) lymphoproliferative disorder lymphomatoid papulosis (LyP), which currently has no approved treatment. OBJECTIVE: To assess the effica...
保存先:
| 出版年: | JAMA Dermatol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Medical Association
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5817433/ https://ncbi.nlm.nih.gov/pubmed/28980004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2017.3593 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|